• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bioorg Chem . Fragment-based discovery of novel Baicalein derivatives as triple-target 3CLpro/PLpro/RdRp inhibitors against SARS-CoV-2

tetano

Editor, Senior Moderator
Bioorg Chem

. 2026 Aug 28:182:110377.
doi: 10.1016/j.bioorg.2026.110377. Online ahead of print.

Fragment-based discovery of novel Baicalein derivatives as triple-target 3CLpro/PLpro/RdRp inhibitors against SARS-CoV-2​


Di Han 1 , Hongkun Yang 2 , Yifan Wang 2 , Fengxiang Liu 2 , Wenfeng Lu 2 , Baoyi Fan 2 , Yuxiao Chang 2 , Meiting Wang 2 , Jiarui Lu 2 , Taigang Liu 2 , Shaoli Cui 3 , Junqiang Zhao 4 , Qinghe Gao 5 , Jingqiang Cui 6 , Yongtao Xu 7

Affiliations Expand


Abstract​


The rapid evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the emergence of drug resistance necessitate the development of multi-target antiviral therapeutics. This study aimed to computationally design a novel triple-target inhibitor derived from the natural flavonoid Baicalein, targeting the essential SARS-CoV-2 enzymes 3CLpro, PLpro, and RdRp to combat viral resistance. An integrated computational approach was employed, including virtual screening of compound libraries, molecular docking using Molecular Operating Environment software, fragment-based drug design to optimize Baicalein, and molecular dynamics simulations over 200 ns with AMBER 18 to assess binding stability. Binding free energies were calculated via MM/GBSA methods, and pharmacokinetic properties were evaluated using ADME/T predictions. Retrosynthetic analysis was performed to confirm synthetic feasibility. The novel compound BD02 demonstrated stable binding to all three targets, with significantly improved binding free energies compared to Baicalein: 3CLpro (-50.68 kcal/mol), PLpro (-59.05 kcal/mol), and RdRp (-51.98 kcal/mol). Molecular dynamics simulations showed low root mean square deviation values, indicating high structural stability. ADME/T predictions revealed favorable drug-like properties, including good absorption and low toxicity risks. BD02 is a computationally promising synthetic lead scaffold for broad-spectrum anti-coronavirus design. This multi-target design theoretically helps mitigate viral resistance and provides structural design references.

Keywords: Baicalein; Computer-aided drug design; Drug design; Molecular dynamics simulation; Multi-target inhibitor; SARS-CoV-2.
 
Back
Top Bottom